** ResMed slumps nearly 10% to $185.30 in premarket trading
** Eli Lilly on Friday said its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials
** ResMed makes ventilators and machines used for non-invasive treatment of sleep apnea, a condition in which the airway is blocked multiple times while sleeping
** Lilly said it had submitted its application to the U.S. FDA to have Zepbound approved as a treatment for obstructive sleep apnea and would submit to other regulatory agencies globally in the coming weeks
** RMD up ~20% YTD compared to 14.6% rise in the S&P 500
(Reporting by Medha Singh)
((medha.singh@thomsonreuters.com))
Comments